Malignant melanoma outcomes have drastically changed in recent years due to the introduction of immune checkpoint inhibitors (ICIs). However, many patients still experience intolerable side effects, therapy resistance, and disease progression on ICI therapy. Therefore, there remains a need for novel therapeutics that address this gap in treatment options. Cell-based therapies have gained wide attention as a therapeutic option that could address this gap in treatment options for advanced melanoma. These therapies work by extracting certain cell types produced in the human body such as T-cells, modifying them based on a specific target, and transfusing them back into the patient. In the realm of cancer therapy, cell-based therapies utilize immune cells to target tumor cells while sparing healthy cells. Recently, the Food and Drug Administration (FDA) has approved the usage of lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy, in advanced melanoma. This came following recent results from the C-144-01 study (NCT02360579), which demonstrated the efficacy and safety of TILs in metastatic melanoma patients who otherwise failed on standard ICI/targeted therapy. Thus, the results of this trial as well as the recent FDA approval have proven the viability of utilizing cell-based therapies to fill the gap in treatment options for patients with advanced melanoma. This review aims to provide a comprehensive overview of major cell-based therapies that have been utilized in melanoma by delineating results of the most recent multi-center phase II/ III clinical trials that evaluate the efficacy and safety of major cell-based therapies in melanoma. Additionally, we provide a summary of current limitations in each cell-based therapeutic option as well as a future direction of how to further extrapolate these cell-based therapies in advanced melanoma.
15 November 2024 in Journal of the American Academy of Dermatology
Background: Central centrifugal cicatricial alopecia (CCCA) is a progressive scarring alopecia that disproportionately impacts Black women. Although research interest in CCCA has grown over time, trends among the most influential publications and the representation of skin of color disparities within the literature have not been systematically evaluated. Objective: The objective of this study was to characterize publication trends, influential contributors, thematic foci, and the representation of skin of color disparities among the top 100 most-cited publications on CCCA. Methods: A bibliometric search was conducted on 1 April 2026 using the Scopus database. The top 100 most-cited publications related to CCCA were identified and analyzed systematically. Co-authorship and keyword co-occurrence analyses were performed using VOSviewer. Representation of skin of color disparities was assessed through keyword-based content analysis of titles, abstracts, and keywords with manual verification. Results: The top 100 most-cited publications on CCCA accumulated a total of 4588 citations and were published between 1968 and 2025. Publication output increased over time, with the greatest number of publications occurring in 2014 and 2018. The most prolific author was M. Miteva, while the Journal of the American Academy of Dermatology was the leading publishing journal, and the University of Miami Miller School of Medicine and Wake Forest University School of Medicine were the top contributing institutions. Sixty-four percent of publications specifically discussed disparities associated with CCCA. Conclusion: The 100 most-cited publications reflect the substantial advancement of our scientific understanding of CCCA. However, CCCA remains comparatively under-represented within hair research, highlighting a need for continued pursuit of high-quality, equity-centered investigation.
Genome integrity is a critical driver of cellular stability, and defects in the processes that maintain genome health are potent sources of cancer progression. Homologous recombination deficiency (HRD), which damages cells through absent or erroneous repair of double-stranded DNA breaks, is a prime example of such cellular dysfunction. Poly(ADP-ribose) polymerase (PARP) inhibitors exploit these aberrancies in the cellular repair process by arresting the ability of the PARP enzyme to repair cellular and genetic damage, inducing the accumulation of DNA damage and cancer cell death. While the utility of PARP inhibitors has been established in many HRD-associated tumors — particularly breast, pancreatic, ovarian, and prostate cancer — less robust evidence exists for the efficacy of PARP inhibitors in melanoma. Increasing efforts are underway to investigate PARP inhibitors as a viable treatment option for advanced and metastatic melanoma, both as monotherapy and in combination with other agents such as immune checkpoint inhibitors and BRAF/MEK inhibitors. Though several gaps in our knowledge of the use of PARP inhibitors in melanoma still exist, promising headway is being made in our understanding of its efficacy and safety. Here, we present a review of the utility of PARP inhibitors in melanoma, current clinical trials, and future avenues for further exploration.
UNSTRUCTURED In this cross-sectional analysis of TikTok content related to central centrifugal cicatricial alopecia (CCCA), physician-created videos demonstrated significantly higher information quality than non-physician content, while discussion of racial disparities and skin-of-color considerations in CCCA were limited across all creators on the platform.